Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in earlyand late-stage cholestasis

World Journal of Gastroenterology

Volumn 23, Issue 42, 2017, Pages 7519-7530

  Gabbia, Daniela ^a   Pozza, Arianna Dalla ^a   Albertoni, Laura ^a   Lazzari, Roberta ^a   Zigiotto, Giorgia ^a   Carrara, Maria ^a   Baldo, Vincenzo ^a   Baldovin, Tatjana ^a   Floreani, Annarosa ^a   De Martin, Sara ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cholestasis; Constitutive androstane receptor; CYP3A; Drug metabolism; Pregnane X receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; GAMMA GLUTAMYLTRANSFERASE; MESSENGER RNA; PREGNANE X RECEPTOR; CELL RECEPTOR; CYP3A1 PROTEIN, RAT; CYP3A2 PROTEIN, RAT; CYTOCHROME P450 3A; STEROID RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA CONTAMINATION; ENZYME KINETICS; ENZYME METABOLISM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HYDROXYLATION; LIMIT OF QUANTITATION; MALE; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RNA EXTRACTION; ANIMAL; ENZYMOLOGY; LIVER; METABOLISM; PATHOLOGY; WISTAR KYOTO RAT;

ANIMALS; CHOLESTASIS; CYTOCHROME P-450 CYP3A; LIVER; MALE; RATS, INBRED WKY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID;

EID: 85034099425     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i42.7519     Document Type: Article

References (42)

1. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-1227 [PMID: 9780343 DOI: 10.1056/NEJM199810223391707]
2. Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010; 139: 1481-1496 [PMID: 20849855 DOI: 10.1053/j.gastro.2010.09.004]
3. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36 Suppl 1: S3-S12 [PMID: 23141891 DOI: 10.1016/S2210-7401(12)70015-3]
4. Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120-1125.e1-12 [PMID: 21334334 DOI: 10.1053/j.gastro.2011.02.044]
5. Halilbasic E, Baghdasaryan A, Trauner M. Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis 2013; 17: 161-189 [PMID: 23540496 DOI: 10.1016/j.cld.2012.12.001]
6. Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007; 27: 920-929 [PMID: 17696930 DOI: 10.1111/j.1478-3231.2007.01506. x]
7. Gonzalez-Sanchez E, Firrincieli D, Housset C, Chignard N. Nuclear Receptors in Acute and Chronic Cholestasis. Dig Dis 2015; 33: 357-366
8. Hrycay E, Forrest D, Liu L, Wang R, Tai J, Deo A, Ling V, Bandiera S. Hepatic bile acid metabolism and expression of cytochrome P450 and related enzymes are altered in Bsep (-/-) mice. Mol Cell Biochem 2014; 389: 119-132 [PMID: 24399466 DOI: 10.1007/s11010-013-1933-y]
9. Chen J, Murray M, Liddle C, Jiang XM, Farrell GC. Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct-ligated male rats: importance to reduced hepatic content of cytochrome P450 in cholestasis. Hepatology 1995; 22: 580-587 [PMID: 7635428]
10. Chen J, Farrell GC. Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: relevance to drug metabolism in experimental cholestasis. J Gastroenterol Hepatol 1996; 11: 870-877 [PMID: 8889968 DOI: 10.1111/j.1440-1746.1996. tb00095.x]
11. Bastien MC, Leblond F, Pichette V, Villeneuve JP. Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. Can J Physiol Pharmacol 2000; 78: 912-919 [PMID: 11100940 DOI: 10.1139/y00-066]
12. Agüero RM, Favre C, Rodriguez-Garay EA. Inhibitory effect of short-term bile duct ligation on hepatic cytochrome P450 of bile acid-depleted rats. Pathobiology 2001; 69: 30-35 [PMID: 11641615 DOI: 10.1159/000048755]
13. Fukushima S, Okuno H, Shibatani N, Nakahashi Y, Seki T, Okazaki K. Effect of biliary obstruction and internal biliary drainage on hepatic cytochrome P450 isozymes in rats. World J Gastroenterol 2008; 14: 2556-2560 [PMID: 18442205 DOI: 10.3748/wjg.14.2556]
14. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos 1996; 24: 940-947 [PMID: 8886602]
15. Jan YH, Mishin V, Busch CM, Thomas PE. Generation of specific antibodies and their use to characterize sex differences in four rat P4503A enzymes following vehicle and pregnenolone 16alphacarbonitrile treatment. Arch Biochem Biophys 2006; 446: 101-110 [PMID: 16448623 DOI: 10.1016/j.abb.2005.11.019]
16. Palatini P, De Martin S, Pegoraro P, Orlando R. Enzyme inhibition and induction in liver disease. Curr Clin Pharmacol 2008; 3: 56-69 [PMID: 18690879 DOI: 10.2174/157488408783329896]
17. Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: An update. World J Gastroenterol 2016; 22: 1260-1278 [PMID: 26811663 DOI: 10.3748/wjg.v22.i3.1260]
18. Tarcin O, Basaranoglu M, Tahan V, Tahan G, Sücüllü I, Yilmaz N, Sood G, Snyder N, Hilman G, Celikel C, Tözün N. Time course of collagen peak in bile duct-ligated rats. BMC Gastroenterol 2011; 11: 45 [PMID: 21527001 DOI: 10.1186/1471-230X-11-45]
19. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F, Laleman W. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014; 59: 2286-2298 [PMID: 24259407 DOI: 10.1002/hep.26939]
20. De Martin S, Gabbia D, Albertin G, Sfriso MM, Mescoli C, Albertoni L, Paliuri G, Bova S, Palatini P. Differential effect of liver cirrhosis on the pregnane X receptor-mediated induction of CYP3A1 and 3A2 in the rat. Drug Metab Dispos 2014; 42: 1617-1626 [PMID: 25030308 DOI: 10.1124/dmd.114.058511]
21. Floreani M, De Martin S, Gabbia D, Barbierato M, Nassi A, Mescoli C, Orlando R, Bova S, Angeli P, Gola E, Sticca A, Palatini P. Severe liver cirrhosis markedly reduces AhR-mediated induction of cytochrome P450 in rats by decreasing the transcription of target genes. PLoS One 2013; 8: e61983 [PMID: 23626760 DOI: 10.1371/journal.pone.0061983;]
22. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699 [PMID: 7560864 DOI: 0168827895802266]
23. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45 [PMID: 11328886]
24. Dimauro I, Pearson T, Caporossi D, Jackson MJ. A simple protocol for the subcellular fractionation of skeletal muscle cells and tissue. BMC Res Notes 2012; 5: 513 [PMID: 22994964 DOI: 10.1186/1756-0500-5-513]
25. Tag CG, Sauer-Lehnen S, Weiskirchen S, Borkham-Kamphorst E, Tolba RH, Tacke F, Weiskirchen R. Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J Vis Exp 2015; 96 [PMID: 25741630 DOI: 10.3791/52438]
26. Kobayashi K, Urashima K, Shimada N, Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 2002; 63: 889-896 [PMID: 11911841 DOI: 10.1016/S0006-2952(01)00843-7]
27. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007; 39: 699-721 [PMID: 18058330 DOI: 10.1080/03602530701690374]
28. Farrell GC, Zaluzny L. Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver. Aust J Exp Biol Med Sci 1984; 62 (Pt 3): 291-301 [PMID: 6497779]
29. Ene MD, Roberts CJ. Pharmacokinetics of nifedipine after oral administration in chronic liver disease. J Clin Pharmacol 1987; 27: 1001-1004 [PMID: 3437063 DOI 10.1002/j.1552-4604.1987. tb05604.x]
30. George J, Liddle C, Murray M, Byth K, Farrell GC. Pretranslational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 1995; 49: 873-881 [PMID: 7741759 DOI: 10.1016/0006-2952(94)00515-N]
31. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 2012; 83: 1112-1126 [PMID: 22326308 DOI: 10.1016/j.bcp.2012.01.030]
32. Rudraiah S, Zhang X, Wang L. Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? Annu Rev Pharmacol Toxicol 2016; 56: 605-626 [PMID: 26738480 DOI: 10.1146/annurev-pharmtox-010715-103209]
33. Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci USA 2005; 102: 2063-2068 [PMID: 15684063 DOI: 10.1073/pnas.0409794102]
34. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 2001; 98: 3375-3380 [PMID: 11248086 DOI: 10.1073/pnas.051014398]
35. Saini SP, Sonoda J, Xu L, Toma D, Uppal H, Mu Y, Ren S, Moore DD, Evans RM, Xie W. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 2004; 65: 292-300 [PMID: 14742670 DOI: 10.1124/mol.65.2.292]
36. Staudinger JL, Woody S, Sun M, Cui W. Nuclear-receptormediated regulation of drug- and bile-acid-transporter proteins in gut and liver. Drug Metab Rev 2013; 45: 48-59 [PMID: 23330541 DOI: 10.3109/03602532.2012.748793]
37. Oladimeji P, Cui H, Zhang C, Chen T. Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk. Expert Opin Drug Metab Toxicol 2016; 12: 997-1010 [PMID: 27295009 DOI: 10.1080/17425255.2016.1201069]
38. Pavek P. Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-Talk of PXR with Other Nuclear Receptors via Coactivator Interactions. Front Pharmacol 2016; 7: 456 [PMID: 27932985 DOI: 10.3389/fphar.2016.00456]
39. Jonker JW, Liddle C, Downes M. FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol 2012; 130: 147-158 [PMID: 21801835 DOI: 10.1016/j.jsbmb.2011.06.012]
40. Renga B, Migliorati M, Mencarelli A, Cipriani S, D'Amore C, Distrutti E, Fiorucci S. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim Biophys Acta 2011; 1809: 157-165 [PMID: 21296199 DOI: 10.1016/j.bbagrm.2011.01.008]
41. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001; 98: 3369-3374 [PMID: 11248085 DOI: 10.1073/pnas.051551698]
42. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221 [PMID: 15917386 DOI: 10.1056/NEJMra032424]